Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

REPORT DESCRIPTION
Companion Diagnostics Market is Expected to Reach USD 5.6 Billion Globally in
2019: Transparency Market Research
Transparency Market Research published new market report “Companion Diagnostics
Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma
and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,
2013 - 2019," the global companion diagnostics market was valued at USD 1.8 billion in
2012 and is expected to grow at a CAGR of 18.1% from 2013 to 2019, to reach an
estimated value of USD 5.6 billion in 2019.
Companion diagnostics are the tests or assays which assist physicians in making efficient
treatment decisions depending on the patient response to the ongoing treatment. These
tests are developed either once the drug is commercialized or along with the drug in
development. The diagnostic test acts as a companion to the drug under investigation and
ensures the commercialization of a safer and efficient targeted therapeutic in a very cost
effective manner. The most important factors favoring growth of the global companion
diagnostics market include the increasing focus of pharmaceutical manufacturers on cost
reduction in drug discovery and development, and the rising demand for targeted therapies.
Transparency Market Research
Companion Diagnostics
Market - Global Industry
Analysis, Size, Share,
Growth, Trends and
Forecast, 2013 – 2019
Single User License: US $ 4595
Multi User License: US $ 7595
Corporate User License: US $ 10595
Buy Now
Request Sample
Published Date: Aug 2013
84 Pages Report

Also, continuous exploration of biomarkers and advances in diagnostic technologies will
drive the growth and acceptance of companion diagnostics worldwide.
Factors such as lack of compact regulatory guidelines for the development and
commercialization of companion diagnostics, high cost of procedures, lengthy
developmental and approval phases, and lack of proper reach and availability (particularly in
the low income countries) are expected to hamper the ready acceptance of companion
diagnostics. Currently, many in vitro diagnostics companies are focusing on the
development of accurate and reliable companion diagnostics for various biomarkers.
Pharmaceutical companies are either focusing on in-house development of companion
diagnostics or development in collaboration with diagnostics companies. This strategy
focusing on the co-development of a drug and its companion diagnostic will prove to be
advantageous over the conventional development process occurring in isolation.
The global companion diagnostics market can be categorized by tests for various indications
and geography. Companion diagnostics market for breast cancer was the most prominent
segment of the market in 2012 by revenue. Extensive research on breast cancer biomarkers
and a paradigm shift towards personalized medicine will continue to propel the adoption of
breast cancer companion diagnostics. However, another attractive segment of this market is
that of lung cancer companion diagnostics, with the discovery of lung cancer specific
biomarkers and an elaborate pipeline of related companion diagnostics for the same. It is
estimated that the global market for lung cancer companion diagnostics will grow at a CAGR
of over 20% from 2013 to 2019.
At a regional level, North America was the largest market in 2012 for companion
diagnostics, followed by the European region. The favorable healthcare policies, large
consumer base, high disposable incomes, increased awareness, presence of suitable
infrastructure facilities and ready acceptance of novel approaches in medicine will propel
rapid development of companion diagnostics in the North American market. The Asia-Pacific
and RoW regions are expected to experience commendable growth by 2019 due to the huge
untapped potential, rising disposable incomes and continuous improvements in healthcare
infrastructure.
Related & Recently Published Reports by Transparency Market Research
In Vitro Diagnostics Market: http://www.transparencymarketresearch.com/in-vitro-
diagnostic-tests.html
Pain Management Devices Market: http://www.transparencymarketresearch.com/pain-
management-drugs-devices.html
Microscopy Devices Market: http://www.transparencymarketresearch.com/microscopy-
market.html
The companion diagnostics market is characterized by the presence of established
diagnostics manufacturers as well as small players solely operating in this market. The
major companies competing in this market are Roche Holdings AG, Qiagen N.V., Abbott

Laboratories, Agilent Technologies, Inc., Genomic Health, Inc., GE Healthcare Ltd., Life
Technologies Corporation, and Agendia N.V.
The global companion diagnostics market is segmented as follows:
Companion Diagnostics Market, by Indications
 Breast Cancer
 Lung Cancer
 Colorectal Cancer
 Gastric Cancer
 Melanoma
 Others (HIV, Thalassemia)
Companion Diagnostics Market, by Geography
 North America
 Europe
 Asia-Pacific
 Rest of the World (RoW)
TABLE OF CONTENTS
Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 List Of Abbreviations
Chapter 2 Executive Summary

Browse the full report at
http://www.transparencymarketresearch.com/companion-diagnostics-
market.html
Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
3.2.1 Rising Need For Companion Diagnostics Along With Targeted Therapies
3.2.2 Increasing Demand As Well As Developmental Efforts Towards Personalized
Medicine
3.2.3 The Pharmacoeconomic Advantage: Reduced Drug Development Costs
3.2.4 Increasing Cancer Incidence Worldwide
3.2.5 Impact Analysis Of Market Drivers
3.3 Market Restraints
3.3.1 Effect Of Influence Of Advocacy Groups And Clinical Societies
3.3.2 Prolonged Developmental And Approval Phases
3.3.3 Impact Analysis Of Market Restraints
3.4 Market Opportunities
3.4.1 Expansion Into Newer Indication Areas
3.5 Porter’s Five Force Analysis: Global Companion Diagnostics Market
3.5.1 Bargaining Power Of Buyers
3.5.2 Bargaining Power Of Suppliers
3.5.3 Threat Of Substitutes
3.5.4 Threat Of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Companion Diagnostics Market, By Geography,
2012

Chapter 4 Companion Diagnostics Market, By Indications, 2011 - 2019 (USD
Million)
4.1 Introduction
4.1.1 Comparative Analysis: Global Companion Diagnostics Market, By Indication, 2012
& 2019 (Value %)
4.1.2 Breast Cancer
4.1.3 Lung Cancer
4.1.4 Colorectal Cancer
4.1.5 Gastric Cancer
4.1.6 Melanoma
4.1.7 Others (HIV, Thalassemia)
Chapter 5 Companion Diagnostics Market, By Geography, 2011 - 2019 (USD
Million)
5.1 Overview
5.1.1 Comparative Analysis: Global Companion Diagnostics Market, By Geography,
2012 & 2019 (Value %)
5.2 North America
5.2.1 North America Companion Diagnostics Market Size And Forecast, 2011 - 2019
(USD Million)
5.3 Europe
5.3.1 Europe Companion Diagnostics Market Size And Forecast, 2011 - 2019 (Usd
Million)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Companion Diagnostics Market Size And Forecast, 2011 - 2019 (USD
Million)
5.5 Rest Of The World (Row)
5.5.1 Row Companion Diagnostics Market Size And Forecast, 2011 - 2019 (USD Million)

market.html
Chapter 6 Competitive Landscape
6.1 Market Share By Key Players, 2012 (%)
Chapter 7 Recommendations
7.1 Changing Business Models of Pharmaceutical and Diagnostics Manufacturers
7.2 Investing in Emerging Economies
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 Agendia N.V.
8.3 Agilent Technologies, Inc.,

8.4 Biogenex Laboratories, Inc.
8.5 Ge Healthcare Ltd.
8.6 Genomic Health, Inc.
8.7 Laboratory Corporation Of America Holdings (Labcorp)

8.8 Life Technologies Corporation
8.9 Qiagen N.V.
8.10 Resonance Health Analysis Services Pty Ltd.
8.11 Roche Holdings Ag
8.12 Siemens Healthcare

About Us:
Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street, Suite 700, Albany
NY – 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
market.html

Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Recomendados

Recomendados

Más contenido relacionado

Último

Último (20)

Destacado

Destacado (20)

Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019